FibroFind, a preclinical Contract Research Organization, has appointed Lee Borthwick as CEO.
Previously, Borthwick, a FibroFind co-founder and translational research expert, was the company’s Chief Scientific Officer. He takes over the CEO role from his colleague and co-founder, Jelena Mann, who remains with the business as non-executive director, providing strategic scientific oversight and guidance.
Three new senior hires are also joining the team:
- Mark Chadwick has been appointed as Chief Business Officer, bringing more than 30 years’ experience across biotech, CRO, and platform technology companies. He is responsible for leading commercial strategy and building partnerships with biopharma clients.
- Laurence Provost has been appointed as Chief Financial Officer. He brings a wealth of experience in private equity-backed and high-growth environments and is responsible for building the firm’s financial and operational infrastructure to support the scaling business.
- Andy Black has been appointed as Chair. With years of industry experience and a track record of scaling a global life sciences service business to a successful exit, Black will provide the governance and strategic oversight to guide the company’s growth.
“Taking on the role as CEO is an important next step for me and the business as we embark on the next stage of our growth trajectory,” Borthwick remarked. “My focus over the next 12 months will be to help scale the business and our operations to serve the needs of our growing client base and be recognized as the global benchmark for human-relevant evidence in discovery and preclinical decision-making. I’m extremely proud of how far we’ve come as a team to date, and now Mark, Laurence, and Andy have joined we are all set to bolster that growth to the next level and help ensure the most promising treatments reach patients.”
